186 related articles for article (PubMed ID: 31161828)
1. Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI).
Matza LS; Brazier JE; Stewart KD; Pinto L; Bender RH; Kircik L; Jordan J; Kim KJ; Mutebi A; Viswanathan HN; Menter A
J Med Econ; 2019 Sep; 22(9):936-944. PubMed ID: 31161828
[No Abstract] [Full Text] [Related]
2. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
Pickard AS; Gooderham M; Hartz S; Nicolay C
J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
[TBL] [Abstract][Full Text] [Related]
3. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
Su J; Liu T; Li S; Zhao Y; Kuang Y
J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
[No Abstract] [Full Text] [Related]
4. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
[TBL] [Abstract][Full Text] [Related]
5. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Changes in Psoriasis Area and Severity Index by Body Region on Quality of Life in Patients with Psoriasis.
Sojević Timotijević Z; Majcan P; Trajković G; Relić M; Novaković T; Mirković M; Djurić S; Nikolić S; Lazić B; Janković S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):215-222. PubMed ID: 29252174
[TBL] [Abstract][Full Text] [Related]
7. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.
Armstrong AW; Parsi K; Schupp CW; Mease PJ; Duffin KC
JAMA Dermatol; 2013 May; 149(5):577-82. PubMed ID: 23426158
[TBL] [Abstract][Full Text] [Related]
8. How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden.
Geale K; Henriksson M; Schmitt-Egenolf M
Health Qual Life Outcomes; 2017 Jul; 15(1):151. PubMed ID: 28754116
[TBL] [Abstract][Full Text] [Related]
9. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
[TBL] [Abstract][Full Text] [Related]
10. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
12. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
[TBL] [Abstract][Full Text] [Related]
13. Artificial Intelligence-Based Psoriasis Severity Assessment: Real-world Study and Application.
Huang K; Wu X; Li Y; Lv C; Yan Y; Wu Z; Zhang M; Huang W; Jiang Z; Hu K; Li M; Su J; Zhu W; Li F; Chen M; Chen J; Li Y; Zeng M; Zhu J; Cao D; Huang X; Huang L; Hu X; Chen Z; Kang J; Yuan L; Huang C; Guo R; Navarini A; Kuang Y; Chen X; Zhao S
J Med Internet Res; 2023 Mar; 25():e44932. PubMed ID: 36927843
[TBL] [Abstract][Full Text] [Related]
14. Body surface area measurement and soft clustering for PASI area assessment.
Hani AF; Prakasa E; Nugroho H; Affandi AM; Hussein SH
Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():4398-401. PubMed ID: 23366902
[TBL] [Abstract][Full Text] [Related]
15. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis.
Sampogna F; Sera F; Mazzotti E; Pasquini P; Picardi A; Abeni D;
Arch Dermatol; 2003 Mar; 139(3):353-8; discussion 357. PubMed ID: 12622629
[TBL] [Abstract][Full Text] [Related]
16. Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index.
Keetharuth AD; Rowen D; Bjorner JB; Brazier J
Value Health; 2021 Feb; 24(2):281-290. PubMed ID: 33518035
[TBL] [Abstract][Full Text] [Related]
17. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.
Rencz F; Gulácsi L; Péntek M; Poór AK; Sárdy M; Holló P; Szegedi A; Remenyik É; Brodszky V
Br J Dermatol; 2018 Nov; 179(5):1102-1108. PubMed ID: 29968311
[TBL] [Abstract][Full Text] [Related]
18. A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis.
Matza LS; Phillips G; Dewitt B; Stewart KD; Cella D; Feeny D; Hanmer J; Miller DM; Revicki DA
Med Decis Making; 2020 Oct; 40(7):897-911. PubMed ID: 33016238
[TBL] [Abstract][Full Text] [Related]
19. Physical and psychologic measures are necessary to assess overall psoriasis severity.
Kirby B; Richards HL; Woo P; Hindle E; Main CJ; Griffiths CE
J Am Acad Dermatol; 2001 Jul; 45(1):72-6. PubMed ID: 11423838
[TBL] [Abstract][Full Text] [Related]
20. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
